Pliant Therapeutics, Inc.

NasdaqGS:PLRX Stock Report

Market Cap: US$648.7m

Pliant Therapeutics Valuation

Is PLRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PLRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PLRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PLRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PLRX?

Key metric: As PLRX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PLRX. This is calculated by dividing PLRX's market cap by their current book value.
What is PLRX's PB Ratio?
PB Ratio1.9x
BookUS$345.82m
Market CapUS$648.70m

Price to Book Ratio vs Peers

How does PLRX's PB Ratio compare to its peers?

The above table shows the PB ratio for PLRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.5x
TERN Terns Pharmaceuticals
1x-10.1%US$394.1m
OCS Oculis Holding
9.2x6.2%US$937.5m
MNMD Mind Medicine (MindMed)
1.9x42.8%US$522.9m
RAPP Rapport Therapeutics
1.9x-26.3%US$609.0m
PLRX Pliant Therapeutics
1.9x15.9%US$648.7m

Price-To-Book vs Peers: PLRX is good value based on its Price-To-Book Ratio (1.9x) compared to the peer average (3.5x).

Price to Book Ratio vs Industry

How does PLRX's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
RLMD Relmada Therapeutics
0.2x8.4%US$10.68m
PRPH ProPhase Labs
0.2x77.4%US$10.14m
MSTH Mystic Holdings
0.2xn/aUS$4.34m
SHWZ Medicine Man Technologies
0.02xn/aUS$3.21m
PLRX 1.9xIndustry Avg. 1.6xNo. of Companies24PB012345+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PLRX is expensive based on its Price-To-Book Ratio (1.9x) compared to the US Pharmaceuticals industry average (1.6x).

Price to Book Ratio vs Fair Ratio

What is PLRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PLRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PLRX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PLRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.75
US$40.18
+273.8%
11.4%US$47.00US$32.00n/a11
Jan ’26US$13.17
US$40.18
+205.1%
11.4%US$47.00US$32.00n/a11
Dec ’25US$13.80
US$40.18
+191.2%
11.4%US$47.00US$32.00n/a11
Nov ’25US$14.52
US$40.18
+176.7%
11.4%US$47.00US$32.00n/a11
Oct ’25US$10.55
US$40.18
+280.9%
11.4%US$47.00US$32.00n/a11
Sep ’25US$13.29
US$41.36
+211.2%
10.2%US$47.00US$32.00n/a11
Aug ’25US$14.35
US$41.82
+191.4%
11.3%US$48.00US$32.00n/a11
Jul ’25US$10.86
US$41.82
+285.1%
11.3%US$48.00US$32.00n/a11
Jun ’25US$12.13
US$41.08
+238.7%
12.5%US$48.00US$32.00n/a12
May ’25US$12.66
US$43.00
+239.7%
13.6%US$54.00US$33.00n/a12
Apr ’25US$14.81
US$43.00
+190.3%
13.6%US$54.00US$33.00n/a12
Mar ’25US$16.54
US$42.67
+158.0%
12.4%US$50.00US$33.00n/a12
Feb ’25US$18.42
US$45.92
+149.3%
11.4%US$53.00US$34.00US$10.7512
Jan ’25US$18.11
US$45.92
+153.5%
11.4%US$53.00US$34.00US$13.1712
Dec ’24US$14.15
US$46.36
+227.7%
11.3%US$53.00US$34.00US$13.8011
Nov ’24US$14.84
US$48.67
+227.9%
13.9%US$63.00US$35.00US$14.5212
Oct ’24US$17.34
US$48.31
+178.6%
13.7%US$63.00US$35.00US$10.5513
Sep ’24US$16.80
US$48.08
+186.2%
13.7%US$63.00US$35.00US$13.2913
Aug ’24US$17.51
US$48.62
+177.6%
12.4%US$63.00US$40.00US$14.3513
Jul ’24US$18.12
US$48.62
+168.3%
12.4%US$63.00US$40.00US$10.8613
Jun ’24US$21.75
US$48.62
+123.5%
12.4%US$63.00US$40.00US$12.1313
May ’24US$22.31
US$48.92
+119.3%
13.2%US$63.00US$40.00US$12.6612
Apr ’24US$26.60
US$48.27
+81.5%
10.3%US$58.00US$40.00US$14.8111
Mar ’24US$31.43
US$49.09
+56.2%
11.6%US$60.00US$40.00US$16.5411
Feb ’24US$34.45
US$49.09
+42.5%
11.6%US$60.00US$40.00US$18.4211
Analyst Price Target
Consensus Narrative from 11 Analysts
US$40.18
Fair Value
73.2% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 06:01
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pliant Therapeutics, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward NashCanaccord Genuity
Pete StavropoulosCantor Fitzgerald & Co.
David LebowitzCitigroup Inc